In an early-stage scientific trial, six contributors with peanut allergy confirmed improved tolerance to small peanut exposures as much as 4 months after they obtained fecal microbiome transplant utilizing stool capsules.
The outcomes of the Section 1 scientific trial, printed in Science Translational Drugs on Wednesday, suggests fecal microbiome transplant has the potential to be a viable therapy possibility for peanut allergy, in keeping with specialists.
“We, because the meals allergy group, have been ready for these outcomes,” mentioned Stephen Tilles, an allergist-immunologist and scientific professor on the College of Washington, who was not part of this examine. Tilles described the examine findings as “very thrilling,” even when it will not be “prepared for prime time” but.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans

